Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deacon, C. F.
Right arrow Articles by Holst, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deacon, C. F.
Right arrow Articles by Holst, J. J.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:1588-1597, 2001
© 2001 by the American Diabetes Association, Inc.

Dipeptidyl Peptidase IV Inhibition Reduces the Degradation and Clearance of GIP and Potentiates Its Insulinotropic and Antihyperglycemic Effects in Anesthetized Pigs

Carolyn F. Deacon1, Patricia Danielsen1, Letty Klarskov2, Mette Olesen2, and Jens J. Holst1

1 Medical Physiology and
2 Experimental Medicine, The Panum Institute, University of Copenhagen, Copenhagen, Denmark

Glucose-dependent insulinotropic peptide (GIP) is known to be degraded by dipeptidyl peptidase IV (DPP IV), forming an inactive metabolite, but the extent of the enzyme’s role in regulating the biological activity of GIP in vivo is still largely unknown. In nonfasted anesthetized pigs given an intravenous infusion of GIP, the intact peptide (determined by a novel NH2-terminally directed radioimmunoassay) accounts for only 14.5 ± 2.5% of total immunoreactivity. This is increased (to 40.9 ± 0.9%, P < 0.0001) by coadministration of valine-pyrrolidide (a specific DPP IV inhibitor) at a dose that completely inhibits plasma DPP IV activity. The plasma t1/2 of intact GIP is prolonged by the inhibitor (from 3.3 ± 0.3 to 8.1 ± 0.6 min; P < 0.001), whereas the t1/2 for COOH-terminal immunoreactivity is unaffected (13.2 ± 0.5 and 11.5 ± 0.8 min, pre- and postinhibitor). Measurement of arteriovenous concentration differences revealed that the liver, kidney, and extremities are the main sites of removal of exogenous intact GIP (organ extractions, 28.0 ± 2.2, 26.3 ± 5.7, and 21.8 ± 3.0%, respectively). These organ extractions are reduced (P < 0.02) but not eliminated (kidney and extremities) by valine-pyrrolidide (to 6.5 ± 4.6, 14.1 ± 3.1, and 13.9 ± 2.4%, respectively). Valine-pyrrolidide potentiates the insulinotropic effect of GIP (P < 0.02), resulting in an enhanced glucose disappearance rate (k, from 8.0 ± 0.5 to 15.5 ± 2.2%/min; P < 0.01) and a reduction in the glucose excursion after an intravenous glucose load (area under the curve, from 133 ± 23 to 75 ± 9 min · mmol/l; P < 0.05). These results suggest that DPP IV plays an important role in GIP metabolism but is not the sole enzyme responsible for its NH2-terminal degradation. Nevertheless, DPP IV inhibition increases the proportion of intact peptide sufficiently to enhance its insulinotropic and antihyperglycemic effects.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
B. J. Lamont and D. J. Drucker
Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat Fed Mice
Diabetes, January 1, 2008; 57(1): 190 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. J. Drucker
Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action
Diabetes Care, June 1, 2007; 30(6): 1335 - 1343.
[Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
J. Ryskjaer, C. F Deacon, R. D Carr, T. Krarup, S. Madsbad, J. Holst, and T. Vilsboll
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Eur. J. Endocrinol., September 1, 2006; 155(3): 485 - 493.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. F. Deacon, A. Plamboeck, M. M. Rosenkilde, J. de Heer, and J. J. Holst
GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations
Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E468 - E475.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Alana, J. C. Parker, V. A. Gault, P. R. Flatt, F. P. M. O'Harte, J. P. G. Malthouse, and C. M. Hewage
NMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water
J. Biol. Chem., June 16, 2006; 281(24): 16370 - 16376.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
L. A. Nikolaidis, D. Elahi, Y.-T. Shen, and R. P. Shannon
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2401 - H2408.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. F. Burkey, X. Li, L. Bolognese, B. Balkan, M. Mone, M. Russell, T. E. Hughes, and P. R. Wang
Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 688 - 695.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C.-H. Chien, L.-H. Huang, C.-Y. Chou, Y.-S. Chen, Y.-S. Han, G.-G. Chang, P.-H. Liang, and X. Chen
One Site Mutation Disrupts Dimer Formation in Human DPP-IV Proteins
J. Biol. Chem., December 10, 2004; 279(50): 52338 - 52345.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Diabetes, September 1, 2004; 53(9): 2181 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. Trebbien, L. Klarskov, M. Olesen, J. J. Holst, R. D. Carr, and C. F. Deacon
Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs
Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E431 - E438.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Hansotia, L. L. Baggio, D. Delmeire, S. A. Hinke, Y. Yamada, K. Tsukiyama, Y. Seino, J. J. Holst, F. Schuit, and D.J. Drucker
Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors
Diabetes, May 1, 2004; 53(5): 1326 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
Diabetes, March 1, 2004; 53(3): 654 - 662.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. A. Hinke, S. Manhart, K. Kuhn-Wache, C. Nian, H.-U. Demuth, R. A. Pederson, and C. H. S. McIntosh
[Ser2]- and [Ser(P)2]Incretin Analogs: COMPARISON OF DIPEPTIDYL PEPTIDASE IV RESISTANCE AND BIOLOGICAL ACTIVITIES IN VITRO AND IN VIVO
J. Biol. Chem., February 6, 2004; 279(6): 3998 - 4006.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.